Market Size of Global Bladder Cancer Therapeutics and Diagnostics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.00 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Bladder Cancer Therapeutics and Diagnostics Market Analysis
The bladder cancer therapeutics and diagnostics market is poised to grow at a CAGR of 4% over the forecast period.
COVID-19 had a significant impact on the growth of the studied market. For instance, according to the study published in June 2022, titled "The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands" the number of BC diagnoses fell by 14% during the first COVID wave but rose back to pre-COVID levels by the end of 2020 (600 diagnoses a month). Treatment-related alterations were kept to a minimum and adhered to the revised guidelines. During the first wave, the surgical volume was not compromised. Overall, the impact of the initial COVID-19 outbreak on bladder cancer care in the Netherlands appears to be less severe than that documented for other solid tumors in the Netherlands and elsewhere. Additionally, as per the updates from American Urological Association's May 2022, during the peak of the COVID-19 pandemic in 2020, more than a quarter of patients with bladder cancer experienced care delays in the United States. 76,984 (27.2%) patients reported that their treatment was changed, delayed, or canceled as a result of the pandemic, including bladder cancer (27.5%). As a result of the pandemic, the market for bladder cancer therapeutics and diagnostics had been significantly impacted.
The bladder cancer therapeutics and diagnostics market may witness rapid growth due to the increasing awareness about bladder diseases and available therapies, along with growing healthcare expenditure and the growing burden of bladder cancer. For instance, in March 2022, the 'Don't Go Red' theme for Bladder Cancer Awareness has been declared by World Bladder Cancer Patient Coalition to raise awareness of warning signs and symptoms, as early detection is critical for enhancing long-term survival and quality of life. Such initiatives are expected to boost market growth over the forecast period.
Additionally, the increasing prevalence of bladder cancer across the world supports the market expansion over the forest period. For Instance, the Global Cancer Observatory Statistics 2020 reported that bladder cancer and prostate cancer are among the top 10 high incidence cancer around the world. The same source also reported that in 2020, the estimated number of new cases of bladder cancer was 573,278, and that of prostate cancer was 1,414,259 cases among both sexes in the year 2020. Such a high incidence of cancer worldwide is propelling the market over time.
Additionally, various strategies adopted by the key market players, such as product launches and mergers and acquisitions, are anticipated to drive the market over the forecast period. For Instance, in August 2021, Merck, known as MSD outside of the United States and Canada, reported a label update for KEYTRUDA, Merck's anti-PD-1 treatment, in first-line advanced urothelial carcinoma (bladder cancer) in the United States.
Thus, all aforementioned factors are expected to boost the market growth. However, the rise in the number of patent expiration and increased use of the generic drug may restrain the market growth.
Bladder Cancer Therapeutics and Diagnostics Industry Segmentation
As per the scope of the report, bladder cancer is a tumor that starts in the cells of the bladder. Bladder cancer is the rapid, uncontrolled growth of abnormal cells in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. Several therapies have been developed to treat bladder cancers, which, in turn, build a high demand for the bladder cancer therapeutics market. The Bladder Cancer Therapeutics and Diagnostics Market is segmented by Product (Therapeutics (Chemotherapy, Immunotherapy, Other Therapeutics), and Diagnostics (Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics), Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types), and Geography (North America, Europe, Asia- Pacific, Middle East and Africa and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the abovementioned segments.
| By Product | ||||||
| ||||||
|
| By Cancer Type | |
| Transitional Cell Bladder Cancer | |
| Squamous Cell Bladder Cancer | |
| Other Cancer Types |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Bladder Cancer Therapeutics and Diagnostics Market Size Summary
The bladder cancer therapeutics and diagnostics market is expected to experience steady growth over the forecast period, driven by increasing awareness of bladder diseases, rising healthcare expenditure, and the growing burden of bladder cancer globally. The market's expansion is supported by initiatives such as the World Bladder Cancer Patient Coalition's awareness campaigns, which emphasize the importance of early detection for improving survival rates. The prevalence of bladder cancer, which ranks among the top ten high-incidence cancers worldwide, further propels market growth. Key market players are actively engaging in strategies like product launches and mergers and acquisitions to enhance their market presence. However, challenges such as patent expirations and the rise of generic drugs may pose constraints to market growth.
The North American region holds a significant share of the market, attributed to its robust healthcare infrastructure and active research and development activities. The presence of numerous biopharmaceutical companies in the region contributes to the market's size and growth potential. The demand for bladder cancer diagnostics and treatment is anticipated to rise, driven by the increasing incidence of the disease. The market is moderately competitive, with major players like AstraZeneca, Bristol-Myers Squibb, and Pfizer focusing on innovation and expansion to capture a larger market share. Technological advancements in diagnostic procedures, such as the adoption of cystoscopy and the development of new devices, are expected to further support market growth.
Global Bladder Cancer Therapeutics and Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Awareness on Bladder Diseases and Available Therapies
-
1.2.2 Increasing Healthcare Expenditure
-
1.2.3 Increasing Burden of Bladder Cancer
-
-
1.3 Market Restraints
-
1.3.1 Rise in the Number of Patent Expiration and Increased Use of Generic Drugs
-
1.3.2 Asymptomatic Nature of the Disease
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - in USD million)
-
2.1 By Product
-
2.1.1 Therapeutics
-
2.1.1.1 Chemotherapy
-
2.1.1.2 Immunotherapy
-
2.1.1.3 Other Therapeuticss
-
-
2.1.2 Diagnostics
-
2.1.2.1 Cystoscopy
-
2.1.2.2 Bladder Ultrasound
-
2.1.2.3 Urinalysis
-
2.1.2.4 Other Diagnostics
-
-
-
2.2 By Cancer Type
-
2.2.1 Transitional Cell Bladder Cancer
-
2.2.2 Squamous Cell Bladder Cancer
-
2.2.3 Other Cancer Types
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Bladder Cancer Therapeutics and Diagnostics Market Size FAQs
What is the current Global Bladder Cancer Therapeutics and Diagnostics Market size?
The Global Bladder Cancer Therapeutics and Diagnostics Market is projected to register a CAGR of 4% during the forecast period (2024-2029)
Who are the key players in Global Bladder Cancer Therapeutics and Diagnostics Market?
Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Johnson & Johnson (Janssen Pharmaceutical), F. Hoffmann-La Roche and Merck & Co. Inc. are the major companies operating in the Global Bladder Cancer Therapeutics and Diagnostics Market.
